TENELIGLIPTIN 20mg. IP + METFORMIN 1000mg. IP

An antihyperglycemic medicine that is primarily indicated for the management of type 2 diabetes mellitus. Lowes blood glucose levels and improves glycemic control in subjects with type 2 diabetes. Improves blood glucose levels and β-cells function with low risk of hypoglycemia in patients with type 2 diabetes mellitus. (Xiaoxuan Li X. H., 2018) An effective treatment approach for adults diagnosed with Type 2 Diabetes who have not shown sufficient improvement through diet and exercise routines. (Scott, 2015) Demonstrates positive outcomes in terms of glycemic control and effectiveness in managing type 2 diabetes. (M. K. Kim, 2015) Shows a substantial decrease in HbA1c levels among individuals with Type 2 Diabetes without elevating the likelihood of hypoglycemia. (Andrew Bryson, 2016) A well-tolerated and effective drug in enhancing glucose management in patients with type 2 diabetes. (Linong Ji, 2021) Exerts a beneficial effect on pancreatic β-cells and improves pancreatic function. (Xiaoxuan Li X. H., 2018) Possesses a high potency of inhibiting dipeptidyl peptidase-4 activity as compared to sitagliptin, saxagliptin, alogliptin, linagliptin, and vildagliptin. (Seiichi Tanaka, 2014) Shows significant reductions in HbA1c and FPG levels in inadequately controlled type 2 diabetes patients with metformin therapy. (Linong Ji, 2021)